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The newly developed derivatives of nalidixic
acid, the fluoroquinolones, have been studied
extensively in the laboratory and in clinical
trials. Compared with nalidixic acid the new
quinolones exhibit an expanded antimicrobial
spectrum, greatly enhanced bactericidal
activity, and substantial pharmacokinetic
advantages. Numerous clinical studies have
proved the efficacy and safety of these
compounds for various infections in adult
patients.
Many experts have advised against
performing studies on the efficacy and safety of
these promising agents in children because of
potential adverse effects, limited activity
against streptococci, and lack of adequate
pharmacokinetic evaluation. In particular, the
risk of cartilage toxicity in weight-bearing
joints, which was observed in experiments with
some young animals whose skeletal growth
was incomplete, was thought to represent a
contraindication for the use of quinolones in
paediatric patients.
When administered to immature animals
(dogs, rabbits, rats, marmosets, pigs) all the
quinolones studied—older and newer
derivatives—caused arthropathic effects in
major, usually weight-bearing synovial joints
(Gough etal., 1979; Schluter, 1986, 1989;
Christ, Lehnert & Ulbrich, 1988; Burkhardt
et al., 1990; Stahlmann et al., 1990). This arth-
ropathy evolves within days to weeks and is
characterized by cartilage toxicity accom-
panied by non-inflammatory joint effusion.
Histopathological findings are localized blister
formation and erosions in joint cartilage
(Gough et al., 1979; Schluter, 1986; Christ
et al., 1988). Ousters of chondrocytes are
found, indicating attempted cartilage repair.
Recently, electron microscopic examination of
such cartilage showed necrotic chrondrocytes
and dissolution of matrix (Burkhardt et al.,
1990; Stahlmann et al., 1990). These quino-
lone-induced cartilage lesions are usually
irreversible, and the reduced quality of carti-
lage may promote degeneration, including
arthropathia deformans. If clinically sympto-
matic, such arthropathy in animals manifests
as acute arthritis, including limp and swelling.
These toxic effects are dose-dependent, but
occur at different dosages in different species.
Moreover, animal cartilage toxicity varies
between quinolone compounds: this could be
ascribed to either true heterogeneity of atthro-
pathogenicity or differences in pharmaco-
kinetics. In all these animal experiments
the older compounds (e.g. pipedimic
acid, nalidixic acid) showed substantially
greater arthropathogenicity than the
fluoroquinolones.
The pathogenesis of quinolone-induced
arthropathy in animals remains unexplained.
The primary target of all quinolones is a
bacterial DNA gyrase (topoisomerase II), an
essential bacterial enzyme for DNA replication
and certain aspects of transcription, DNA
repair, recombination, and transposition
(Smith, 1986). Although it is generally
accepted that the fluoroquinolones are specific
for prokaryotic enzymes, there are reports of
in-vitro experiments indicating some inhibition
of eukaryotic DNA replication (Castora,
Vissering & Simpson, 1983; Gootz, Barrett &
Sutcliffe, 1990). In immature rats dosed with
ofloxacin, chondrocytes of the intermediate
zone showed a transient decrease and sub-
sequent increase in uptake of tritiated thymi-
dine (Kato & Onodera, 1988). This
observation could reflect early depression of
DNA synthesis by the drug followed by repar-
ative reaction of the chondrocytes. The hypo-
thesis that quinolones might inhibit
mitochondrial DNA in immature, metaboli-
cally active chondrocytes of certain animal
species requires further investigation.
Because of the obvious advantages of the
fluoroquinolones and the absence of joint
pathology in follow-up studies of children
treated with nalidixic acid (Schaad &
Wedgwood, 1987; Adam, 1989), many paedia-
tricians have started to prescribe these anti-
bacterial agents for some of their patients on a
compassionate use basis. By early 1992,
published data on fluoroquinolone use in chil-
dren included over 1000 pre-pubertal patients
(Black et al., 1990; Cheesbrough et al., 1991;
Chysky etal., 1991; LeBel, 1991; Schaad,
1991). These studies report good to excellent
efficacies, and usually mild and always revers-
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ible adverse reactions in 5-15%. So far, there
is no documented case of unequivocal quino-
lone-induced arthropathy in humans.
Reversible arthralgia with possible or probable
relation to quinolone therapy occurred in
approximately 1% of patients, most of whom
were adolescents with cystic fibrosis (LeBel,
1991). In older patients with cystic fibrosis,
arthropathies are estimated to occur in 7-8%
(Phillips & David, 1986). The majority of these
joint diseases are either explained by hyper-
immune mechanisms (so-called cystic fibrosis
arthropathy) or by hypertrophic pulmonary
osteoarthropathy. Definite diagnosis of these
arthropathies is often difficult, and is only
possible after exclusion of coincidental joint
disease. Therefore, the relationship of joint
symptoms to drug therapy in patients with
cystic fibrosis requires very cautious
interpretation.
Many studies have stressed the excellent
sensitivity of magnetic resonance imaging
(MRI) in detecting early and discrete inflam-
matory, degenerative, or traumatic lesions of
articular cartilage under both clinical and
experimental conditions. MRI investigations
performed in juvenile beagle dogs and piglets
were found to predict dprofloxacin-induced
cartilage toxicity at the knee joint (Schluter,
1989; Hoffman & Desprechins, 1991). In these
animal experiments the formation of minimal
intra-articular effusions, manifested by
enlargement of the recessus suprapatellaris,
was the first sign of quinolone-induced
arthropathy.
We conducted clinical, laboratory, radio-
logical and MRI studies in 13 pre-pubertal
(age range 6-13 years) and five post-pubertal
patients (age range 14—24 years) with cystic
fibrosis. Investigations were made at the start
and the end of a three-month course of cipro-
floxacin (30 mg/kg/day, administered orally in
two equal doses) and at follow-up examina-
tions, 4 to 6 and 15 to 22 months later (Schaad
et al., 1991). Our comprehensive monitoring
gave no evidence for arthropathogenicity.
Detailed physical skeletal function tests, height
velocity values, laboratory studies of bone
metabolism, and conventional radiographs of
both knees revealed no abnormalities.
Moreover, serial MRI of the left knee demon-
strated lack of joint effusion, intact two-layer
appearance of cartilage, and unaffected thick-
ness of articular cartilage measured at five
anatomically different points.
Recently, two of our pre-pubertal patients
with far-advanced cystic fibrosis died due to
combined respiratory and cardiac failure, at
the age of 7 and 13 years, respectively. Both
patients had repeatedly received oral courses
of ctprofloxacin (30 mg/kg/day in two doses),
amounting to a total of 9-10 months of quino-
lone treatment during their last three years of
life. In both patients autopsy of the -left knee
revealed macroscopically regular structures.
There were no histopathological changes
similar to those found in animal experiments,
such as blister formation or erosions in joint
cartilage (Schluter, 1989; Burkardt et al., 1990;
Stahhnann et al., 1990). Also, electron micro-
scopic examination showed regular morpho-
logy of hyaline cartilage with intact
chondrocytes, normal mitochondria and
genuine matrix. Details of these studies will be
published elsewhere.
Our clinical, MRI and histopathological
monitoring of ciprofloxacin use, together with
the published experiences of other groups,
suggest that the quinolone antibiotics do not
cause arthropathy in humans. Interspecies
differences may account for the lack of quino-
lone-induced cartilage toxicity in children
compared with juvenile animals. We wish to
stress the need for further studies on potential
quinolone toxicities to be performed in larger
numbers of paediatric patients, including
infants and young children, and in diseases
other than cystic fibrosis. Also, long-term
follow-up over many years is needed.
Nevertheless, it is our strong opinion that
the data presented here justify the compassio-
nate use of the fluoroquinolones in paediatric
patients suffering from specific infections
complicated by pathological or special condi-
tions. Conditions that potentially qualify for
quinolone use include oral anti-pseudomonal
therapy for pulmonary exacerbation in cystic
fibrosis, complicated urinary tract infection
(disturbed urinary outflow due to anatomical
or functional abnormality), and skeletal, aural
and shunt infections. In addition to these rare
indications, there is urgent need in developing
countries for availability of the new quino-
lones for treating children with endemic and
epidemic shigellosis and typhoid fever.
U. B. SCHAAD
J. WEDGWOOD
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In November the British Society for
Antimicrobial Chemotherapy will be cele-
brating 21 years since its inception. The foun-
dation of the Society was based on the desire
to promote knowledge, awareness and
research into all aspects of antimicrobial
chemotherapy. These objectives have clearly
flourished. The Society is well known for the
excellence of its scientific meetings, the
influence of the Reports of its various Working
Parties, its key role in fostering research and
international outreach through the promotion
of joint Society meetings. This Journal,
founded by the Society in 1975, has played a
major role in promoting the scientific effort of
the Society across the broad field of anti-
microbial chemotherapy. Congratulations to
all those members, past and present, who have
contributed to this success story. The article on
page 417 and the scientific programme of the
Autumn Meeting adopt an appropriate stance
which allows reflection on some aspects of the
past, while looking at present and future
aspects of antimicrobial science.
ROGER G. FINCH
Editor-in-Chief
